Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Dermatology
  • Dermatology News
  • Tapinarof cream safe...

Tapinarof cream safe and effective therapy for long-term in patients with plaque psoriasis

Medha BaranwalWritten by Medha Baranwal Published On 2023-05-16T11:45:42+05:30  |  Updated On 16 May 2023 11:11 AM GMT
Tapinarof cream safe and effective therapy for long-term in patients with plaque psoriasis
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • koo
  • Email

USA: Continuous and intermittent use of tapinarof cream in the PSOARING 3 trial was demonstrated to be safe and effective for up to 1 year in adults with mild to severe psoriasis, a recent study in the Journal of the American Academy of Dermatology has shown.Once-daily 1% tapinarof cream showed a high rate of complete disease clearance, continued and durable improvements in health-related...

USA: Continuous and intermittent use of tapinarof cream in the PSOARING 3 trial was demonstrated to be safe and effective for up to 1 year in adults with mild to severe psoriasis, a recent study in the Journal of the American Academy of Dermatology has shown.

Once-daily 1% tapinarof cream showed a high rate of complete disease clearance, continued and durable improvements in health-related quality of life (HRQoL), positive perceptions of tapinarof cream, and high rates of patient satisfaction

Psoriasis is a common inflammatory skin disease that affects HRQoL through pain, itching, and disfigurement. Many patients reported that psoriasis had a moderate to extremely high impact on their daily lives. Important treatment goals for patients include regaining disease control, confidence in therapy, achieving/maintaining clear skin, and symptom relief. Low patient satisfaction with psoriasis therapies and adverse effects on HRQoL are barriers to optimal care. About half of the patients are dissatisfied with their current psoriasis treatment, with patient preferences and satisfaction closely related to treatment adherence. Low treatment satisfaction may be due to adverse events and insufficient efficacy, linked to increased use of combination therapy, treatment discontinuation, and medication switching. Consequently, patient-reported outcomes (PROs) and evaluations of patient satisfaction with treatment are critical considerations for clinicians.

Against the above background, Jerry Bagel, Psoriasis Treatment Center of New Jersey, NJ, USA, and colleagues aimed to assess long-term, health-related quality of life and patient satisfaction with tapinarof, a first-in-class, nonsteroidal, aryl hydrocarbon 131 receptor (AhR) agonist approved by the US FDA (Food and Drug Administration) for plaque psoriasis treatment in adults.

Tapinarof cream 1% once daily had shown significant efficacy and was well tolerated versus vehicle in two 12-week, phase 3 pivotal trials in people with mild to severe plaque psoriasis.

Patients who completed the 12-week trials were suitable for 40 weeks of open-label tapinarof based on PSOARING 3, with a 4-week follow-up. DLQI (Dermatology Life Quality Index) was evaluated at every visit; PSQ (Patient Satisfaction Questionnaire) responses were assessed at week 40 or early termination.

The study led to the following findings:

· 763 eligible patients were enrolled; 78.5% completed the PSQ.

· There was an improvement in DLQI scores which were maintained.

· 68.0% of patients had a DLQI of 0 or 1 by Week 40, suggesting no impact of psoriasis on health-related quality of life.

· Most patients strongly agreed or agreed with all PSQ questions evaluating confidence in tapinarof and satisfaction with efficacy, application ease and cosmetic elegance, and preference for tapinarof versus prior psoriasis therapies.

"Tapinarof cream 1% QD represents a novel, nonsteroidal therapeutic option for patients with plaque psoriasis," the researchers concluded.

Reference:

Bagel J, Gold LS, Del Rosso J, Johnson S, Yamauchi P, Brown PM, Bhatia N, Moore AY, Tallman AM. Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial. J Am Acad Dermatol. 2023 May 10:S0190-9622(23)00771-5. doi: 10.1016/j.jaad.2023.04.061. Epub ahead of print. PMID: 37172733.


Journal of the American Academy of DermatologyPSOARING 3 trial
Source : Journal of the American Academy of Dermatology
Medha Baranwal
Medha Baranwal

    MSc. Biotechnology

    Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Journal Club Today

    Health News Today

    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X